Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | DUO results: duvelisib or ofatumumab monotherapy for R/R CLL?

Stephan Stilgenbauer • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia Duvelisib Ofatumumab
DUO

The Phase III DUO trial investigated duvelisib vs. ofatumumab for chronic lymphocytic leukemia (CLL) in the relapsed/refractory setting (NCT02004522). Here, Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, tells us about the final results of the trial, speaking from the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Stephan Stilgenbauer

2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
Stephan Stilgenbauer • 11 Dec 2023
2:52
Acquired mutations associated with resistance to BTKi in patients with CLL
Stephan Stilgenbauer • 11 Dec 2023
2:51
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
Stephan Stilgenbauer • 11 Dec 2023
2:11
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL
Stephan Stilgenbauer • 11 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals